OPUVIZ™ is one of the first wave aflibercept biosimilars in EuropeOPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen’s partnershipEC ...

Happenings in Boston’s life sciences ecosystem this past week include the departure of a general partner from Apple Tree Partners for another firm, Kronos Bio seeks "strategic alternatives" and new ...

OPUVIZ is one of the first wave aflibercept biosimilars in Europe OPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen's partnership ...

Sage Therapeutics' run of bad news has continued with a failed phase 2 trial of dalzanemdor as a treatment for cognitive ...

Epicore Biosystems (Epicore), a digital health solutions company developing advanced sweat-sensing wearables, today announced that it has been named to Fast Company's fourth annual Next Big Things in ...

Sage Therapeutics Inc.'s stock (SAGE) fell 2.4% Wednesday, headed for a fresh all-time low after the company said it would cease developing a treatment for cognitive impairment associated with ...

According to Alnylam’s Tim Mooney, mivelsiran’s endurance is due to stabilizing tweaks the scientists made to the siRNA ...

Welcome to Cambridge Elements, an innovative concept in academic publishing. Cambridge Elements combine the best features of books and journals to create a quick, concise publishing solution for ...

Tonight will be dry with clear spells for a time, but cloud will move in from the west later, bringing spells of rain and a risk of hill sleet in the early hours. Strengthening winds. Sunday ...

A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, demonstrating significant improvement in ...

Also Read: Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial The results were shared at the American College of Rheumatology ...

Needham forecasts Biogen revenues to remain stable until 2025, rising ~3% by 2026. Biogen will face ongoing challenges as expectations for Leqembi need to adjusted to more realistic levels.